The final, formatted version of the article will be published soon.
REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1459655
This article is part of the Research Topic Reviews In Neuropharmacology 2023:
Microbiota Gut-Brain Axis, Therapeutic Insights for Neurodegenerative Diseases View all 5 articles
Gut Microbiota Metabolites: Potential Therapeutic Targets for Alzheimer's Disease?
Provisionally accepted- 1 College of Traditional Chinese Medicine, Changchun University of Chinese Medicine,, Changchun, Hebei Province, China
- 2 Research Center of Traditional Chinese Medicine, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, Hebei Province, China
- 3 The Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China
- 4 Independent researcher, Changchun, China
Background: Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive decline in cognitive function, which significantly increases pain and social burden. However, few therapeutic interventions are effective in preventing or mitigating the progression of AD. An increasing number of recent studies support the hypothesis that the gut microbiome and its metabolites may be associated with upstream regulators of AD pathology.In this review, we comprehensively explore the potential mechanisms and currently available interventions targeting the microbiome for the improvement of AD. Our discussion is structured around modern research advancements in AD, the bidirectional communication between the gut and brain, the multi-target regulatory effects of microbial metabolites on AD, and therapeutic strategies aimed at modulating gut microbiota to manage AD.The gut microbiota plays a crucial role in the pathogenesis of AD through continuous bidirectional communication via the microbiota-gut-brain axis. Among these, microbial metabolites such as lipids, amino acids, bile acids and neurotransmitters, especially sphingolipids and phospholipids, may serve as central components of the gut-brain axis, regulating AD-related pathogenic mechanisms including β-amyloid metabolism, Tau protein phosphorylation, and neuroinflammation. Additionally, interventions such as probiotic administration, fecal microbiota transplantation, and antibiotic use have also provided evidence supporting the association between gut microbiota and AD. At the same time, we propose an innovative strategy for treating AD: a healthy lifestyle combined with targeted probiotics and other potential therapeutic interventions, aiming to restore intestinal ecology and microbiota balance.Conclusions: Despite previous efforts, the molecular mechanisms by which gut microbes act on AD have yet to be fully described. However, intestinal microorganisms may become an essential target for connecting the gut-brain axis and improving the symptoms of AD. At the same time, it requires joint exploration by multiple centers and multiple disciplines.
Keywords: AD & Gut Microbiota Metabolites-Drug Targets Gut microbial metabolites, Alzheimer's disease, microbiome-gut-brain axis, Metabolites, treatments
Received: 04 Jul 2024; Accepted: 05 Sep 2024.
Copyright: © 2024 Zhang, Lu, Jin, Xu, Zhang, Chen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jian Wang, The Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.